Skip to main content
. 2020 Sep 4;142(16):1562–1578. doi: 10.1161/CIRCULATIONAHA.119.044444

Figure 7.

Figure 7.

Effect of growth factor treatment of engineered heart tissue(EHT) under serum-free conditions.

A, Effect of growth factor treatment (GFs; 20 ng/mL transforming growth factor [TGF]-β1, 10 ng/mL basic fibroblast growth factor [bFGF], 20 ng/mL insulin-like growth factor 1 [IGF-1], 10 ng/mL endothelial growth factor [EGF]) on force under serum-free conditions. n=10–15 EHTs from 2 batches per group. B and C, Quantification of hypoxia-inducible factor 1α (HIF-1α) protein by Western blot of wild-type and DNA methyltransferase (DNMT) 3A−/− EHTs cultured either with serum-free medium or with serum-free medium containing GFs. Loading control = ERK1/2; n=3 EHTs per group. D, Relative transcript abundance of glycolytic genes in DNMT3A−/− EHTs after 1 week of serum-free culture ± GFs. n=3, values normalized to wild-type (dashed line). Effect of GF treatment on glucose consumption (E) and lactate generation (F) of wild-type and DNMT3A−/− EHTs. n=4, values normalized to wild-type (dashed line). ns indicates nonsignificant, *P<0.05, **P<0.01, ***P<0.001.